Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
And Medusa19 do have some serious people on their team.....the Chief Development Officer can bring AffiDX to the market without breaking sweat:
Christian Stephenson has over 24 years experience in the medical devices industry. Working for a range of multinational blue-chip companies (Smith&Nephew, KCI, 3M ) and start-up / SME’s (Crawford Health Care & Lantor). His career has primarily focussed on R&D and strategic portfolio development, and building teams with market-leading track records of delivery. Christian’s last role was Vice President of R&D for KCI, the largest wound care company globally, where he was responsible for the whole wound care pipeline and global R&D team. Prior to this position, Christian led the R&D, Regulatory and Quality team at Crawford Healthcare, developing from scratch a wound care portfolio, which rapidly became the 3rd largest in the UK, with Kerrmax becoming the number 1 brand in the medical device market. Christian was part of the management team that ultimately led to the successful sale of Crawford.
Christian holds a degree in Chemistry from the University of Hull and has numerous publications and patents.
Mark Goldberg's CV says he doesn't do guessing so my reading is he KNOWS that AVA 6000 really works. As Royal Marsden Oncology is world famous Dr Goldberg probably knows (and likely worked) with some of the senior people. I'm happy to believe he got the nod. One or two posters believe that because he's 67 he's looking for a retirement pasture....that amazing CV says otherwise. He doesn't do no-hopers and 67 is nothing in this day and age....ask Warren Buffet at 91 or Mick Jagger at 78.
The actual start date for these trials was 16th July (clinicaltrials.gov) so its quite possible that by the time of Avacta's RNS on the 11th August (AS said earlier that dosing would be end of July) the first patient was already about three weeks into the treatment, and benefitting from it. I don't believe Avacta would announce dosing the day after beginning. Just in case.
So all in all it tells me that Dr Mark A Goldberg has found something so compelling it's prompted him to move out of his US comfort zone and take a seat on a board in grey and dank Wetherby (I was born a few miles away so I'm allowed to say it).
Social media leakage by the end of September?
Lda .... not exactly correct . Calibre is licensed to sell across Europe and BioServUK is their UK trading name. We don't know if Calibre is stockpiling on the continent or supplying direct from GAD. Just another known unknown.
4 August: Is Alastair Smith telling porky pies? Yes or no?
"Manufacturing scale up continues to progress well and we remain focused on the challenge of being able to supply the clear demand in the market.
"We continue to see significant levels of commercial interest from around the world and are progressing a number of opportunities in a range of sectors. I look forward to updating the market on further developments."
Blow to Oxford Nanopore after ministers end Covid testing contract early
Vaccine rollout ends need for biotech firm's tests, deemed a 'life-saving innovation' by former health secretary Matt Han****
Britain's brightest biotech firm, Oxford Nanopore, has been dealt a blow after the Government ended a £113m contract for its Covid tests early despite deeming the tests “life-saving innovations”.
In filings on Companies House, Oxford Nanopore said the Department for Health had decided against taking all the Covid tests it had agreed to buy.
Oxford Nanopore did not disclose how many tests the Government had signed up for, but ministers paid £113m for the kits, suggesting a significant order size. Part of the order was fulfilled.
Oxford Nanopore's 90-minute tests use saliva to tell whether someone has Covid and do not require swabs, making them easier and quicker to conduct.
In the depths of the pandemic, Oxford Nanopore's tests had been deemed a “life-saving innovation” by then-health secretary Matt Han****. Last August, he said the tests formed a key pillar of the UK's efforts to "break chains of transmission quickly" by providing on-the-spot results for people in care homes and hospitals.
However, Oxford Nanopore revealed that, in April, the Department for Health determined that it “no longer had a requirement for our product”, as the vaccination rollout meant fewer people needed testing, and ended the contract before taking delivery of all the tests.
The deal would have provided a major boost to Oxford Nanopore's revenues ahead of its blockbuster London listing expected later this year.
Analysts have suggested the company could be priced anywhere between £4.5bn and £16bn, putting it among the most valuable floats in the City's history and coming as a boon for the LSE, which has been desperate to attract more biotech leaders.
In March, chief executive Dr Gordon Sanghera said: “We believe that an IPO is the start of the next phase of our journey.
“Gaining access to deeper, international pools of capital would support our growth plans, enhancing our ability to innovate and scale our manufacturing and commercial functions. 2020 was a pivotal year for us.
“However, it is clear to us that we are still only in the foothills of what is possible.”
Despite the government contract ending early, Oxford Nanopore expected revenues to keep rising this year, with indicative growth of more than 80pc in its life science research tool division in the first half. It said it already had other contracts agreed that suggested further revenue growth over the course of the next 18 months.
It comes after a stellar year for Nanopore, which also makes DNA sequencing tools that can track Covid mutations and which have been used for a fifth of all Covid sequencing globally.
Revenues last year hit £114m - more than double the £52m for 2019. Even stripping out the Covid bump from last year, Oxford Nanopore's revenue was up 26pc compa
SureScreen has been approved for a while hasn’t it?
-------------------------------------------------------------------
Re-badged Chinese stuff. A joke web site that doesn't work. Glorified street traders so probably perfect for Downing Street.
Advena Ltd on the label also reminds us that Calibre is licensed to sell across Europe. Does this mean a central storehouse in say Belgium has a large shipment available, or are they warehoused in the half dozen biggest EU economies? A shame we can't get feedback from Spain, or Germany? It would be nice to know if Calibre in Spain is selling as pro-actively as BioserveUK.
https://www.newsweek.com/lambda-covid-variant-1000-cases-us-shows-vaccine-resistance-1615668
The Lambda variant of COVID-19 may be more resistant to vaccines and is highly infectious, researchers at Japan's University of Tokyo have warned in a new scientific paper published on July 28. The study is yet to be peer reviewed.
Like the Delta variant, Lambda is highly transmissible but Japanese researchers believe that three mutations in the variant's spike proteins make it more resistant to antibodies induced by vaccination.
Lambda, which is also known as the C.37 variant, is responsible for 1,037 cases of COVID-19 in the U.S., according to data from the GISAID Initiative, which promotes the rapid sharing of information about influenza and coronaviruses.
I think AS's biggest concern is funding a ramp-up for demand he can't meet. (that was supposed to be the government's job) Calibre sales to the EU and UK are for pro use only so I'm confident SME's will get through the web site.